A new blood test is being developed to improve ovarian cancer diagnosis, with the potential to reduce unnecessary surgery leading to better health outcomes, saving time, stress and money for patients as well as the healthcare system.

Quest Diagnostics on Monday launched the first direct-to-consumer blood test to detect abnormal levels of beta amyloid, a key Alzheimer's disease protein that can appear years before dementia symptoms arise.

Beckman Coulter Diagnostics, a clinical diagnostics leader, and Fujirebio, a leader in neurological markers and In Vitro Diagnostic (IVD) manufacturing, today announced a new partnership combining their respective immunoassay strengths to support therapeutic development, clinical trials, reimbursement, and routine clinical adoption in the field of neurodegenerative diseases.

Qiagen on Thursday announced a systematic review and publication of the clinical relevance of test values from its QuantiFeron-TB Gold Plus TB1 and TB2 blood collection tubes.

A blood test identified patients with a treatable neurometabolic disease in a prospective trial, suggesting that it can be used to improve diagnosis of a condition that is currently detected using an invasive procedure.

Berry Genomics recently announced that it will acquire NeoGenomics, a US-based blood testing company, for US$2.4 billion to further strengthen its oncology testing business.

Naveris said Wednesday that Mayo Clinic began a Phase II trial of its circulating tumor DNA blood test, NavDx, to guide treatment for patients with HPV-driven head and neck cancer.

In a new study looking at the long-term effects of hospitalized patients who have acute kidney injury, Johns Hopkins Medicine researchers found that higher levels of certain biomarkers in urine and blood can predict a patient’s risk of developing chronic kidney disease.

C2N Diagnostics announced the publication of a study further confirming the sensitivity of its PrecivityAD blood test for diagnosing Alzheimer’s disease.

Astellas Pharma and Roche Diabetes Care Japan have signed an agreement to develop and commercialise the latter’s Accu-Chek Guide Me blood glucose monitoring system as a combined medical product with BlueStar.